首页> 美国卫生研究院文献>other >BLOOD SUBSTITUTES: EVOLUTION FROM NON-CARRYING TO OXYGEN AND GAS CARRYING FLUIDS
【2h】

BLOOD SUBSTITUTES: EVOLUTION FROM NON-CARRYING TO OXYGEN AND GAS CARRYING FLUIDS

机译:血液替代品:从非携带到氧气和气体携带流体的演变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of oxygen (O2) carrying blood substitutes has evolved from the goal of replicating blood O2 transports properties to that of preserving microvascular and organ function, reducing the inherent or potential toxicity of the material used to carry O2, and treating pathologies initiated by anemia and hypoxia. Furthermore, the emphasis has shifted from blood replacement fluid to “O2 therapeutics” that restore tissue oxygenation to specific tissues regions. This review covers the different alternatives, potential and limitations of hemoglobin based O2 carriers (HBOCs) and perfluorocarbon based O2 carriers (PFCOCs), with emphasis on the physiological conditions disturbed in the situation that they will be used. It describes how concepts learned from plasma expanders without O2 carrying capacity can be applied to maintain O2 delivery and summarizes the microvascular responses due to HBOCs and PFCOCs. This review also presents alternative applications of HBOCs and PFCOCs namely: 1) How HBOC O2 affinity can be engineered to target O2 delivery to hypoxic tissues; and 2) How the high gas solubility of PFCOCs provides new opportunities for carrying, dissolving and delivering gases with biological activity. It is concluded that current blood substitutes development has amplified their applications horizon by devising therapeutic functions for oxygen carriers requiring limited O2 delivery capacity restoration. Conversely, full, blood-like O2 carrying capacity re-establishment awaits control of O2 carrier toxicity.
机译:携带氧气(O2)的血液替代品的开发已从复制血液O2传输特性的目标发展为保留微血管和器官功能,降低用于承载O2的材料的固有或潜在毒性以及治疗由贫血引发的病理学的目标和缺氧。此外,重点已从血液替代液转移到“ O2疗法”,以将组织氧合恢复至特定组织区域。这篇综述涵盖了基于血红蛋白的O2载体(HBOC)和基于全氟化碳的O2载体(PFCOC)的不同替代方案,潜力和局限性,重点是在使用它们的情况下受到干扰的生理条件。它描述了如何将从没有O2承载能力的血浆膨胀机学到的概念应用于维持O2的输送,并总结了由于HBOC和PFCOC引起的微血管反应。这篇综述还介绍了HBOC和PFCOC的替代应用,即:1)如何设计HBOC O2亲和力以将O2输送到低氧组织。 2)PFCOC的高气体溶解度如何为携带,溶解和输送具有生物活性的气体提供新的机会。结论是,当前的血液替代品开发通过为需要有限的O2输送能力恢复的氧气载体设计治疗功能,扩大了其应用前景。相反,要重新建立完整的血样O2承载能力,等待控制O2载体毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号